IL202083A0 - Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system - Google Patents
Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous systemInfo
- Publication number
- IL202083A0 IL202083A0 IL202083A IL20208309A IL202083A0 IL 202083 A0 IL202083 A0 IL 202083A0 IL 202083 A IL202083 A IL 202083A IL 20208309 A IL20208309 A IL 20208309A IL 202083 A0 IL202083 A0 IL 202083A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- pharmaceutical compositions
- nervous system
- central nervous
- therapeutic compounds
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94269607P | 2007-06-08 | 2007-06-08 | |
PCT/US2008/066033 WO2008154337A1 (en) | 2007-06-08 | 2008-06-06 | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
US12/134,385 US9808509B2 (en) | 2007-06-08 | 2008-06-06 | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
Publications (1)
Publication Number | Publication Date |
---|---|
IL202083A0 true IL202083A0 (en) | 2010-06-16 |
Family
ID=40096080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL202083A IL202083A0 (en) | 2007-06-08 | 2009-11-12 | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
Country Status (6)
Country | Link |
---|---|
US (2) | US9808509B2 (en) |
EP (1) | EP2152240A4 (en) |
JP (1) | JP2011504163A (en) |
CA (1) | CA2687505C (en) |
IL (1) | IL202083A0 (en) |
WO (1) | WO2008154337A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009100383A2 (en) | 2008-02-07 | 2009-08-13 | University Of Washington | Circumferential aerosol device |
JP5863650B2 (en) | 2009-07-27 | 2016-02-16 | ノシセプタ エルエルシー | Method for treating pain |
FR2948809B1 (en) * | 2009-07-31 | 2012-08-17 | St Microelectronics Rousset | LOW POWER SELF-MINUTE READING AMPLIFIER |
US8592485B2 (en) * | 2010-06-17 | 2013-11-26 | Healthpartners Research Foundation | Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders |
RU2728583C2 (en) | 2011-03-03 | 2020-07-30 | Импел Ньюрофарма Инк. | Device for nasal drug delivery |
EP3851142A1 (en) | 2011-05-09 | 2021-07-21 | Impel NeuroPharma Inc. | Nozzles for nasal drug delivery |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
US20130336928A1 (en) * | 2012-06-18 | 2013-12-19 | Healthpartners Research & Education | Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s) |
ES2880399T3 (en) | 2012-07-27 | 2021-11-24 | Neurodyn Life Sciences Inc | Improved cerebral bioavailability of galantamine through selected formulations and transmucosal administration of lipophilic prodrugs |
CN104507461A (en) * | 2012-07-27 | 2015-04-08 | 神经动力生命科学公司 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
ES2442242B1 (en) * | 2012-08-09 | 2014-11-25 | Biotechnology Institute, I Mas D, S.L. | Composition with growth factors intended for intranasal treatment of a neurodegenerative disease or other pathology of the central nervous system, and its manufacturing method. |
PT2961426T (en) | 2013-02-26 | 2019-12-09 | Baxalta Inc | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
US10279012B2 (en) * | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
WO2014159878A2 (en) | 2013-03-13 | 2014-10-02 | Regents Of The University Of California | Intranasal administration of guanidinylated aminoglycosides |
WO2014169272A1 (en) | 2013-04-12 | 2014-10-16 | Icahn School Of Medicine At Mount Sinai | Method for treating post-traumatic stress disorder |
JP2016520378A (en) | 2013-04-28 | 2016-07-14 | インペル ニューロファーマ インコーポレイテッド | Medical unit dose container |
KR20220119187A (en) | 2013-05-15 | 2022-08-26 | 리젠츠 오브 더 유니버시티 오브 미네소타 | Adeno-associated virus mediated gene transfer to the central nervous system |
US10314911B2 (en) * | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
SI3242676T1 (en) | 2015-01-07 | 2024-02-29 | Tonix Pharma Limited | Magnesium-containing oxytocin formulations and methods of use |
MX2018002895A (en) | 2015-09-10 | 2018-07-06 | Impel Neuropharma Inc | In-line nasal delivery device. |
BR112018071156A2 (en) | 2016-04-15 | 2019-03-12 | The Trustees Of The University Of Pennsylvania | gene therapy to treat mucopolysaccharidosis type ii |
US10449230B2 (en) | 2016-10-06 | 2019-10-22 | The Regents Of The University Of California | Polymyxin derived cell penetrating scaffolds |
EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
JP2021503988A (en) | 2017-11-21 | 2021-02-15 | インペル ニューロファーマ インコーポレイテッド | Intranasal device with inlet interface |
JP7191099B2 (en) | 2017-11-21 | 2022-12-16 | インペル ファーマシューティカルズ インコーポレイテッド | intranasal device with dip tube |
BR112020013750A8 (en) | 2018-01-05 | 2022-10-18 | Impel Neuropharma Inc | INTRANASAL DISPENSE OF OLANZAPINE BY PRECISION OLFATIVE DEVICE |
US20190209463A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of dihydroergotamine by precision olfactory device |
JP2021532098A (en) | 2018-07-19 | 2021-11-25 | インペル ニューロファーマ インコーポレイテッド | Respiratory tract delivery of levodopa and dopa decarboxylase inhibitors for the treatment of Parkinson's disease |
BR112021013244A8 (en) | 2019-01-03 | 2022-10-18 | Impel Neuropharma Inc | NASAL DRUG DELIVERY DEVICE |
EP3969085A4 (en) | 2019-05-17 | 2023-06-21 | Impel Pharmaceuticals Inc. | Single-use nasal delivery device |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2989437A (en) * | 1955-06-08 | 1961-06-20 | Upjohn Co | Anti-inflammatory and anti-bacterial decongestant nasal spray compositions |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US20010053775A1 (en) * | 1998-01-30 | 2001-12-20 | Matthias Seidel | Nasal solutions |
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7112566B1 (en) * | 1999-09-17 | 2006-09-26 | The Regents Of The University Of California | Systemic administration of Hypocretin-1 |
CA2393688A1 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
JP2005524649A (en) * | 2002-02-25 | 2005-08-18 | カイロン コーポレーション | Intranasal administration of MC4-R agonist |
US7071172B2 (en) * | 2002-04-30 | 2006-07-04 | The University Of North Carolina At Chapel Hill | Secretion signal vectors |
US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
US7618615B2 (en) * | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
US7776312B2 (en) | 2004-08-13 | 2010-08-17 | Healthpartners Research Foundation | Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity |
US20090317377A1 (en) | 2005-08-26 | 2009-12-24 | Yeomans David C | Therapy procedure for drug delivery for trigeminal pain |
-
2008
- 2008-06-06 US US12/134,385 patent/US9808509B2/en active Active
- 2008-06-06 EP EP08756757A patent/EP2152240A4/en not_active Withdrawn
- 2008-06-06 WO PCT/US2008/066033 patent/WO2008154337A1/en active Application Filing
- 2008-06-06 JP JP2010511350A patent/JP2011504163A/en active Pending
- 2008-06-06 CA CA2687505A patent/CA2687505C/en not_active Expired - Fee Related
-
2009
- 2009-11-12 IL IL202083A patent/IL202083A0/en unknown
-
2017
- 2017-11-02 US US15/801,437 patent/US10098928B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2687505C (en) | 2013-10-08 |
US20180125940A1 (en) | 2018-05-10 |
EP2152240A1 (en) | 2010-02-17 |
US9808509B2 (en) | 2017-11-07 |
CA2687505A1 (en) | 2008-12-18 |
EP2152240A4 (en) | 2012-05-09 |
US10098928B2 (en) | 2018-10-16 |
WO2008154337A1 (en) | 2008-12-18 |
JP2011504163A (en) | 2011-02-03 |
US20080305077A1 (en) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL202083A0 (en) | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system | |
SG10201401661RA (en) | Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders | |
PT2482812T (en) | Therapeutic uses of pharmaceutical compositions | |
ZA201100034B (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
HK1211889A1 (en) | Therapeutic use of diaminophenothiazines | |
EP2291157A4 (en) | Compositions and methods for the transdermal delivery of pharmaceutical compounds | |
IL193727A0 (en) | Dosage forms for administering combinations of drugs | |
EP2152316A4 (en) | Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system | |
HK1147767A1 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
ZA200905962B (en) | Combination therapy for treatment of immune disorders | |
EP2207802A4 (en) | Intranasal administration of active agents to the central nervous system | |
EP2268140A4 (en) | Novel compounds advantageous in the treatment of central nervous system diseases and disorders | |
HK1141447A1 (en) | Pharmaceutical composition for the treatment of proliferative diseases | |
ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
EP2114415A4 (en) | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | |
PL385972A1 (en) | Pharmaceutical composition for therapy of parodonthium deseases | |
IL206435A0 (en) | Therapeutic regimens for the treatment of immunoinflammatory disorders | |
PL2331092T3 (en) | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer | |
EP2222295A4 (en) | Pharmaceutical composition for treatment and prevention of kidney diseases | |
EP2203174A4 (en) | Therapeutic regimens for the treatment of immunoinflammatory disorders | |
PT2344166E (en) | Pharmaceutical composition for the treatment of gastrointestinal irritation disorders | |
EP2578206A4 (en) | Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system | |
EP2329824A4 (en) | Novel pharmaceutical composition for treatment of nociceptive pain | |
IL209804A0 (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
GB0715256D0 (en) | Benzylthiazolypiperazine derivatives for the treatment of neuro degenerative diseases |